RedHill Biopharma to Present the Positive Results of the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
45
RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium

TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ: RDHL ) (TASE: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that Ira Kalfus, MD, Medical Director at RedHill, will present the positive final results, announced in June 2015, of the first Phase III study with RHB-105 for the treatment of  H. pylori  infection, at the Innovations in Gastroenterology 2017 Symposium, on Friday, January 6, 2017 at 10:15 AM IST, at the Hilton Hotel, Tel Aviv, Israel.

RHB-105 is a proprietary, fixed-dose, oral combination therapy for the eradication of  H. pylori  infection.

The ERADICATE Hp first Phase III study with RHB-105 successfully met its primary endpoint of superiority over historical standard-of-care (SoC) eradication rate of 70%, with high statistical significance (p<0.001). The study results demonstrated 89.4% efficacy in eradicating H. pylori  infection with RHB-105. Notably, subsequent open-label treatment with SoC therapies of patients in the placebo arm of the ERADICATE Hp study demonstrated only 63% eradication rate, further supporting the potential superior efficacy of RHB-105 over SoC.  Treatment with RHB-105 appeared to be safe and well tolerated. A confirmatory Phase III study with RHB-105 is planned to be initiated in the first half of 2017, after completion of an ongoing supportive pharmacokinetic (PK) program.

About RHB-105: RHB-105 is a new and proprietary fixed-dose oral combination therapy of two antibiotics and a proton pump inhibitor (PPI) in an all-in-one oral capsule with a planned indication for the treatment of  H. pylori  infection.  H. pylori  bacterial infection is a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. A first Phase III study with RHB-105 was completed in the U.S. with positive results (the ERADICATE Hp study). The study demonstrated an overall success rate of 89.4% in eradicating H. pylori , and met its protocol-defined primary endpoint of superiority in eradication of  H. pylori  infection over historical standard-of-care efficacy levels of 70%, with high statistical significance (p<0.001) . A confirmatory Phase III study is planned to be initiated in the U.S in the first half of 2017. Additional studies may be required, subject to FDA feedback. RHB-105 has been granted Qualifying Infectious Disease Product (QIDP) designation by the FDA, providing a Fast-Track development pathway, as well as NDA Priority Review status, potentially leading to a shorter NDA review time by the FDA, if filed. If approved, RHB-105 will also receive an additional five years of exclusivity, in addition to the standard exclusivity period, for a total of 8 years of U.S. market exclusivity.

About RedHill Biopharma Ltd.:      RedHill Biopharma Ltd. (NASDAQ: RDHL ) (TASE: RDHL ) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill has a U.S. co-promotion agreement with Concordia for Donnatal ® , a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis. RedHill’s clinical-stage pipeline includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and a completed proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA ® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA ® (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii) RIZAPORT ® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015. More information about the Company is available at: www.redhillbio.com .

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xii) competitive companies and technologies within the Company’s industry; and (xiii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 25, 2016. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

Company contact: Adi Frish Senior VP Business Development & Licensing RedHill Biopharma +972-54-6543-112 adi@redhillbio.com IR contact (U.S.): Marcy Nanus Senior Vice President The Trout Group +1-646-378-2927 Mnanus@troutgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 25

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 19

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 19

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 16

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 80

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 88

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 30

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 5

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading

Top 5 Most Recently Viewed Articles

Homrich Berg Welcomes Tim Tallach as New Tax Director

Updated Category News Views 319

Homrich Berg Welcomes Tim Tallach as Director Atlanta-based Homrich Berg, a prominent fee-only wealth advisor recognized for its comprehensive services, proudly announces the addition of Tim Tallach, J.D., CPA, as its new Director of Advanced Tax Planning and Family Office Services. This important addition to the team aims to fortify the firm's capabilities in serving...

Continue Reading
G-III Apparel Group Schedules First Quarter Earnings Call

Updated Category News Views 168

G-III Apparel Group Prepares for Earnings Announcement G-III Apparel Group, Ltd. (NASDAQ: GIII) is a prominent entity in the global fashion industry, recognized for its innovative design, sourcing, and marketing capabilities. The company has recently made an announcement regarding its first quarter fiscal 2026 earnings. This significant event is scheduled to take place...

Continue Reading
Mediaplanet's Initiative to Empower Small Businesses Nationwide

Updated Category News Views 117

Mediaplanet's Campaign for Small Business Success Small businesses play a pivotal role in stimulating the economy by fostering innovation, generating employment, and enhancing community engagement. However, in the face of today's complex business challenges, many entrepreneurs require support to navigate these waters successfully. To address this need, Mediaplanet has...

Continue Reading
New Barclays Report Highlights AI's Impact on Data Centre Demand

Updated Category News Views 529

Revolutionizing Data Centres: Insights from Barclays Research In a groundbreaking report, Barclays Research reveals that the rising influence of artificial intelligence (AI) could propel data centre usage in the US to triple by 2030. This report, titled “AI revolution: Meeting massive AI infrastructure demands,” presents a comprehensive analysis of how AI's growth...

Continue Reading
Major Renovation Completed at Aloft Phoenix-Airport Hotel

Updated Category News Views 274

Aloft Phoenix-Airport Unveils Major Renovation In an exciting development for travelers, the Aloft Phoenix-Airport has completed a comprehensive renovation that significantly upgrades its facilities. This 143-room hotel, managed by HEI Hotels & Resorts and owned by The RADCO Companies, has refreshed everything from guest rooms to public spaces, ensuring a modern and...

Continue Reading